Oral coenzyme Q10 supplementation in patients with migraine: Effects on clinical features and inflammatory markers

source extracted confidence: high 2026-04-09
#administration-oral #adolescent #adult #anti-inflammatory-agents-non-steroidal #biomarkers

Oral coenzyme Q10 supplementation in patients with migraine: Effects on clinical features and inflammatory markers

Dahri et al., 2019 | Nutr Neurosci | Rct

Citation

Dahri Monireh, Tarighat-Esfanjani Ali, ... Hashemilar Mazyar. Oral coenzyme Q10 supplementation in patients with migraine: Effects on clinical features and inflammatory markers. Nutr Neurosci. 2019-Sep;22(9):607-615. doi:10.1080/1028415X.2017.1421039

Abstract

Backgrounds and aims: Migraine and inflammation are correlated. Coenzyme Q10 (CoQ10) as an anti-inflammatory agent has shown useful effects in other diseases. The present study aimed to assess the effect of CoQ10 supplementation on inflammation and clinical features of migraine. Methods: This randomized double-blind placebo-controlled clinical trial was conducted among 45 non-menopausal women aged 18-50 years, diagnosed for episodic migraine according to the International Headache Society. After one month run-in period, subjects received CoQ10 (400 mg/day CoQ10, n = 23) or placebo (wheat starch, n = 22) for three months. All the patients got prophylactic medication too. Serum CoQ10 concentration, Calcitonin gene-related peptide (CGRP), interleukin (IL)-6, IL-10 and tumor necrosis factor-α (TNF-α) were measured at the beginning and end of the study. Results: CoQ10 supplementation reduced CGRP and TNF-α significantly (p = 0.011 and p = 0.044, respectively), but there were no significant differences in serum IL-6 and IL-10 between the two groups. Significant increase in serum CoQ10 levels was evident with CoQ10 therapy (P < 0.001). A significant improvement was found in frequency (p = 0.018), severity (p = 0.001) and duration (p = 0.012) of migraine attacks in CoQ10 group compared to placebo. Conclusion: CoQ10 supplementation may decrease CGRP and TNF-α with no favorable effects on IL-6 and IL-10 in patients with migraine.

Key Findings

CoQ10 supplementation reduced CGRP and TNF-α significantly (p = 0.011 and p = 0.044, respectively), but there were no significant differences in serum IL-6 and IL-10 between the two groups. Significant increase in serum CoQ10 levels was evident with CoQ10 therapy (P < 0.001). A significant improvement was found in frequency (p = 0.018), severity (p = 0.001) and duration (p = 0.012) of migraine attacks in CoQ10 group compared to placebo. Conclusion: CoQ10 supplementation may decrease CGRP and TNF

Outcomes Measured

  • inflammatory markers

Population

Field Value
Population migraine
Sample Size 23
Age Range aged 18-50
Condition inflammation

MeSH Terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal
  • Biomarkers
  • Double-Blind Method
  • Female
  • Humans
  • Inflammation
  • Inflammation Mediators
  • Middle Aged
  • Migraine Disorders
  • Randomized Controlled Trials as Topic
  • Treatment Outcome
  • Ubiquinone
  • Young Adult

Evidence Classification

  • Level: Rct
  • Publication Types: Journal Article, Randomized Controlled Trial
  • Vertical: coq10-migraine

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09